- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about DSNKY
Recent news which mentions DSNKY
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
From Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
February 06, 2023
From Motley Fool
From Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
From Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
December 09, 2022
From Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
November 14, 2022
From Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
From Benzinga
Why MacroGenics Stock Sank Today
September 12, 2022
From Motley Fool
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
September 12, 2022
From Benzinga
3 Top Stocks to Invest In Right Now
August 16, 2022
From InvestorPlace
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
August 15, 2022
From Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
August 15, 2022
From Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
August 12, 2022
From Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
August 09, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
June 27, 2022
From Benzinga
From Motley Fool
AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
June 06, 2022
From Benzinga
Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
April 27, 2022
From Benzinga
From Benzinga
Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer
April 19, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Here's Why Everyone's Talking About AstraZeneca Right Now
September 21, 2021
From Motley Fool
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
September 20, 2021
From Benzinga
AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer
September 17, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.